Search Result

Results for "

Cyp2c9 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (1) Autophagy (8) Bacterial (4) Calcium Channel (3) COX (2) Cytochrome P450 (32) Endogenous Metabolite (5) FGFR (1) Fungal (1) Histamine Receptor (3) HIV (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (2) Necroptosis (1) NF-κB (2) Parasite (1) Potassium Channel (2) PPAR (8) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) ROCK (1) Sodium Channel (2) URAT1 (2) Virus Protease (2)
By Research Areas:	Cancer (15) Cardiovascular Disease (12) Endocrinology (3) Infection (10) Inflammation/Immunology (12) Metabolic Disease (8) Neurological Disease (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-U00048

Bucolome

Paramidin; Paramidine
Cytochrome P450 Inflammation/Immunology

Bucolome is a CYP2C9 inhibitor, used as an uricosuric agent or anti-inflammatory agent.

Bucolome Paramidin; Paramidine	Cytochrome P450	Inflammation/Immunology
Bucolome is a *CYP2C9* inhibitor, used as an uricosuric agent or anti-inflammatory agent.

HY-N1201

Apigenin Maximum Cited Publications 21 Publications Verification 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1	Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology Cancer
Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0893

Tetrahydrocurcumin 1 Publications Verification HZIV 81-2	Cytochrome P450 Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit *CYP2C9* and CYP3A4.

HY-119996

AR-C141990	Others	Inflammation/Immunology
AR-C141990 (Compound 30) is a potent blocker of the monocarboxylate transporter MCT1 with a K_i of 4.8 nM. AR-C141990 (Compound 30) inhibits CYP3A4 and CYP2C9 with IC₅₀ values of 16 μM .

HY-151251

CYP2C9/CYP2C19-IN-1	Cytochrome P450 Virus Protease	Infection
CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-N1201R

Apigenin (Standard) 4',5,7-Trihydroxyflavone(Standard); Apigenol(Standard); C.I. Natural Yellow 1 (Standard)	Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology Cancer
Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0688

Linderane	Cytochrome P450	Inflammation/Immunology
Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-B0281A

Ranitidine hydrochloride 1 Publications Verification	Histamine Receptor Cytochrome P450 Bacterial	Infection Metabolic Disease Endocrinology
Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and *CYP2C9* .

HY-B0693

Ranitidine	Histamine Receptor Bacterial Cytochrome P450	Infection Metabolic Disease Endocrinology Cancer
Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine is a weak inhibitor of CYP2C19 and *CYP2C9* .

HY-B0258

Gemfibrozil 1 Publications Verification CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-N8382

Chalepensin	Cytochrome P450	Neurological Disease
Chalepensin, a furanocoumarin, is a competitive CYP2A6 inhibitor. Chalepensin also inhibits human CYP1A1, CYP1A2, CYP2A13, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 to different extents .

HY-B0281AS

Ranitidine-d6 hydrochloride	Histamine Receptor Cytochrome P450 Bacterial	Infection Metabolic Disease Endocrinology
Ranitidine-d₆ (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-128859

EMT inhibitor-2	Cytochrome P450	Metabolic Disease
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC₅₀s of 49.72 and 5.54 μM, respectively .

HY-153970

URAT1 inhibitor 7	URAT1	Inflammation/Immunology
URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC₅₀ of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits *CYP2C9, with an IC₅₀* of 4.2 μM. URAT1 inhibitor 7 can be used for gout research .

HY-151253

CYP2C1/CYP2C19-IN-2	Cytochrome P450 Virus Protease	Infection
CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV .

HY-B0258R

Gemfibrozil (Standard) 1 Publications Verification CI-719 (Standard)	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-114759

MS-PPOH	Cytochrome P450	Neurological Disease Metabolic Disease Cancer
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and *CYP2C9* with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-143906

URAT1 inhibitor 2	URAT1	Inflammation/Immunology
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC₅₀ values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated ¹⁴C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .

HY-17356

Fenofibrate 10+ Cited Publications	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-18063

ML252	Potassium Channel Cytochrome P450	Neurological Disease
ML252 is a selective inhibitor of potassium channel, targeting to KCNQ2 channel (Kv7.2) (IC₅₀=69 nM). ML252 also inhibits Cytochrome P450 with IC₅₀s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively .

HY-114415

AWZ1066S	Parasite	Infection
AWZ1066S is a highly potent, specific and orally active anti-Wolbachia agent with EC₅₀ value of 121 nM. AWZ1066S also is a weak CYP2C9 inhibitor and a weak CYP3A4 inducer with IC₅₀ values of 9.7 μM and 37 uM, respectively. AWZ1066S can be used for the research of tropical diseases such as Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) .

HY-100386

Ticlopidine PCR 5332
Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.

HY-144652

IDO1-IN-19	Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450	Cancer
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC₅₀ of *CYP2C9* of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC₅₀s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .

HY-147807

HIV-1 inhibitor-40	HIV Cytochrome P450	Infection
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an EC₅₀ of 1.9 nM. HIV-1 inhibitor-40 displays weak CYP sensitivity with IC₅₀ values of 5.16 μM and 4.51 μM against CYP2C9 and CYP2C19, respectively. HIV-1 inhibitor-40 has no apparent in vivo acute toxicity .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4	PPAR Autophagy Cytochrome P450
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-17356R

Fenofibrate (Standard) 10+ Cited Publications	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-141547

Nav1.7-IN-8	Sodium Channel Cytochrome P450	Inflammation/Immunology
Nav1.7-IN-8 is a potent blockage of NaV1.7 with high selectivity for the inhibition of NaV1.7 over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits *CYP2C9* and CYP3A4 with an IC₅₀ of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain .

HY-100386S

Ticlopidine-d4 PCR 5332-d₄	Isotope-Labeled Compounds Cytochrome P450	Cardiovascular Disease
Ticlopidine-d4 is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively[1]. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively[2][3].

HY-148597

FGFR-IN-10	FGFR Cytochrome P450	Cancer
FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC₅₀s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC₅₀s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively .

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-12946A

BI 653048 phosphate
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-12946

BI 653048
BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-N0043

Ginsenoside Rd Gypenoside VIII	NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca ²⁺ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and *CYP2C9, with IC₅₀*s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

HY-149866

HIV-1 inhibitor-58	Cytochrome P450 HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC₅₀ less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC₅₀: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch .

HY-N2071

Cedrol 1 Publications Verification (+)-Cedrol; α-Cedrol	Cytochrome P450 Fungal	Infection Inflammation/Immunology Cancer
Cedrol is a bioactive sesquiterpene, a potent competitive inhibitor of cytochrome P-450 (CYP) enzymes. Cedrol inhibits CYP2B6-mediated bupropion hydroxylase and CYP3A4-mediated midazolam hydroxylation with K_i of 0.9 μM and 3.4 μM, respectively. Cedrol also has weak inhibitory effect on CYP2C8, CYP2C9, and CYP2C19 enzymes . Cedrol is found in cedar essential oil and poetesses anti-septic, anti-inflammatory, anti-spasmodic, tonic, astringent, diuretic, insecticidal, and anti-fungal activities .

HY-14362

GSK-25	ROCK Ribosomal S6 Kinase (RSK)	Cardiovascular Disease
GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC₅₀=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC₅₀=398 nM, p70S6K: IC₅₀=1 μM). GSK-25 inhibits P450 profile (IC₅₀s of 2.5, 5.2, 2.5 µM for CYP2C9, CYP2D6, CYP3A4, respectively) .

HY-N0043R

Ginsenoside Rd (Standard) Gypenoside VIII (Standard)	NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca ²⁺ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and *CYP2C9, with IC₅₀*s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

HY-B1218

Sulfaphenazole 5+ Cited Publications	Cytochrome P450 Antibiotic Bacterial Necroptosis Apoptosis	Infection Cardiovascular Disease
Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .

Fenofibrate (GMP)	Fluorescent Dye
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

Fenofibrate (GMP)	Biochemical Assay Reagents
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1201

Apigenin Maximum Cited Publications 21 Publications Verification 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1	Structural Classification Classification of Application Fields Flavones Source classification Origanum majorana L. Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Sunscreen Phenols Polyphenols Cosmetic Research Umbelliferae Disease Research Fields Cancer	Autophagy Cytochrome P450 Endogenous Metabolite
Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0893

Tetrahydrocurcumin 1 Publications Verification HZIV 81-2	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Microorganisms Phenols Polyphenols Curcuma longa Inflammation/Immunology Disease Research Fields Cancer Zingiberaceae	Cytochrome P450 Autophagy Endogenous Metabolite
Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit *CYP2C9* and CYP3A4.

HY-N0688

Linderane	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Inflammation/Immunology Disease Research Fields Lindera aggregata (Sims) Kosterm.	Cytochrome P450
Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-N1201R

Apigenin (Standard) 4',5,7-Trihydroxyflavone(Standard); Apigenol(Standard); C.I. Natural Yellow 1 (Standard)	Structural Classification Classification of Application Fields Source classification Origanum majorana L. Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Sunscreen Phenols Cosmetic Research Umbelliferae Disease Research Fields Cancer	Autophagy Cytochrome P450 Endogenous Metabolite
Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N8382

Chalepensin	Structural Classification Natural Products Haloxylon ammodendron (C. A. Mey.) Bunge Source classification Amaranthaceae Plants	Cytochrome P450
Chalepensin, a furanocoumarin, is a competitive CYP2A6 inhibitor. Chalepensin also inhibits human CYP1A1, CYP1A2, CYP2A13, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 to different extents .

HY-N0043

Ginsenoside Rd Gypenoside VIII	Cardiovascular Disease Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Source classification Plants Endogenous metabolite Disease Research Fields Araliaceae Cancer	NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite
Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca ²⁺ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and *CYP2C9, with IC₅₀*s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

HY-N2071

Cedrol 1 Publications Verification (+)-Cedrol; α-Cedrol	Cedrus deodara (Roxburgh) G. Don Classification of Application Fields Pinaceae Terpenoids Sesquiterpenes Source classification Plants Inflammation/Immunology Disease Research Fields Cancer	Cytochrome P450 Fungal
Cedrol is a bioactive sesquiterpene, a potent competitive inhibitor of cytochrome P-450 (CYP) enzymes. Cedrol inhibits CYP2B6-mediated bupropion hydroxylase and CYP3A4-mediated midazolam hydroxylation with K_i of 0.9 μM and 3.4 μM, respectively. Cedrol also has weak inhibitory effect on CYP2C8, CYP2C9, and CYP2C19 enzymes . Cedrol is found in cedar essential oil and poetesses anti-septic, anti-inflammatory, anti-spasmodic, tonic, astringent, diuretic, insecticidal, and anti-fungal activities .

HY-N0043R

Ginsenoside Rd (Standard) Gypenoside VIII (Standard)	Cardiovascular Disease Panax ginseng C. A. Meyer Structural Classification Classification of Application Fields Terpenoids Source classification Plants Endogenous metabolite Disease Research Fields Araliaceae Cancer	NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite
Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca ²⁺ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and *CYP2C9, with IC₅₀*s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-B0281AS

Ranitidine-d6 hydrochloride
Ranitidine-d₆ (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-100386S

Ticlopidine-d4

Ticlopidine-d4 is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively[1]. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively[2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Cyp2c9 Inhibitors

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products